Cardiovascular Health

Ince describes why patients who are considered fragile are often underdiagnosed and undertreated, and that the VOYAGER PAD analyses can encourage the treatment of the fragile population.

The AZALEA-TIMI 71 randomized trial evaluated the safety and tolerability of 2 blinded doses of the novel factor XI inhibitor abelacimab compared with open-label rivaroxaban.

Bonaca also notes that pharmacists can play a key role in educating patients and clinicians about the appropriate use and dosing of antithrombotic drugs for vascular protection.

Harrington discusses how the performance of milvexian in prior phase 2 trials focused on different patient populations creates the foundation for future research.

Sehnert emphasizes that mavacamten treatment benefits were present in both patients with sarcomere mutation positive HCM and sarcomere mutation negative HCM.

Clinically meaningful lowering of blood pressure through reduction in dietary sodium was achieved safely and rapidly in 1 week in a middle-aged and elderly cohort.

Elevated Lp(a), which was previously untreatable, may become treatable in the near future, according to the study investigator.

The SPRINT trial was the first to demonstrate the benefit of further reduction in blood pressure, but it included a limited Asian population and excluded patients with diabetes or history of stroke.

The SELECT trial expands on existing literature that have shown safety and cardiovascular benefit in individuals with diabetes to now also show benefit in obesity.

The American Heart Association published a statement describing the cardiovascular-kidney-metabolic (CKM) construct, specifically highlighting treatment challenges for CKM syndrome.

In most patients who are pregnant or may become pregnant, warfarin is contraindicated due to increased risk of adverse fetal outcomes.

An analysis of the REVOLUTIONIZE II study data showed that there is an unmet need for long-term outpatient treatment of hyperkalemia in patients with CKD.

How pharmacy teams can remove cost barriers to cardiac care.

Without policies to reduce greenhouse gas emissions, the number of cardiovascular-related deaths due to extreme heat could even triple by mid-century.

According to the authors, identifying the degree of disagreement with physicians’ deprescribing recommendations can improve the communication among older adults and their physicians.

Black men had 27% lower odds of an ideal cardiovascular health score compared to White men, whereas Black women had 55% lower odds compared to White women.

White-coat hypertension was diagnosed in 17 of 35 patients who completed out-of-office blood pressure monitoring.

The FDA has issued a Prescription Drug User Fee Act fate of March 26, 2024, for sotatercept (Merck) as treatment for adults with pulmonary arterial hypertension.

Cases highlight an acute subdural hematoma and chronic obstructive pulmonary disease.

Shared decision-making can be better incorporated into cardiovascular care guidelines by including decision aids, such as informational flyers or online tools to help patients.

Heart disease prevention efforts should acknowledge non-biological factors that can cause issues within cardiovascular health rather than relying on decreasing socioeconomic disparities.

A phase 3 study assessing macitentan 75mg treatment for CTEPH was stopped, although another study using macitentan will continue.

Black women had the highest rates of obesity-related cardiovascular disease deaths whereas other racial groups had more men experiencing obesity-related CVD deaths than women.

Although the pandemic has negatively influenced the care that patients with cardiovascular conditions receive, the study authors found that there were not significant inequities regarding patients’ race.

Study finds that statin use is associated with a 12% reduction in the risk of another stroke.

Stressful life events and poor sleeping patterns are linked to the development of atrial fibrillation in older women.

The phase 3 clinical program, CORALreef, consists of 3 trials and is likely the first of its kind for an oral PCSK9 inhibitor, according to the study authors.

Despite study findings showing that 1 in 5 patients hospitalized for COVID-19 developed persistent high blood pressure, many had underlying risk factors.

Pharmacists can actively engage in the implementation of the Comprehensive Diagnostics and Examinations in Acute Coronary Syndromes pathway within the hospital or health care system.